Your Search Returned 153 tagged news reports
Companies Helping to Fight the After-Thanksgiving Day Bulge There a few holidays quite like Thanksgiving. I mean when else do we regularly get a day off toward the middle of the work week, surround ourselves with family and friends, and gorge
To put these numbers into context, the worst selling drug on the top 100 list, Shire 's Adderall, saw sales topping $170 million in the third quarter. Qsymia sales would thus need to grow an astounding 1,500% from current levels to even scratch the
Seth Fischer, CEO of Vivus, said adding nine years to patent coverage -- which shields the company from competitors -- "adds significant value to the Qsymia franchise." With an accumulated deficit of $643.4 million at the end of September, Vivus
There was a lot of excitement when the Food and Drug Administration approved the first obesity drug in more than a decade...However, the initial sales of the drug have disappointed the investors in a big way, and the stock has taken a substantial hit.
Will Orexigen finally start moving forward next year on earnings? Analysts have become more positive about Orexigen's earnings prospects, cutting their loss estimates for the full 2014 year in half in recent months. The stock, though, has moved
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. The Dow Jones Industrials climbed almost 129 points today,
Under the licensing deal, Vivus will receive about $300m based on certain regulatory and sales milestones, including a one-time license fee of $30m and a $15m payment contingent following a potential label amendment regarding onset-of-action as well
Auxilium Pharmaceuticals will get the right to sell Vivus' impotence drug Stendra in the U.S. and Canada as part of a deal between the two companies that could be worth more than $300 million. The deal provides additional funding for Vivus, which is
United States, but both have struggled to get the green light in the European Union. European Medicines Agency for the approval of its obesity medication Contrave...Analysts David Williamson and Max Macaluso discuss this story in the following video.
The market may be crashing lower following a government shutdown, but biotech races on. In particular, three biotechs on Thursday posted very large intraday gains...With 85 fully funded partnership programs, Ligand has one of the largest portfolios